New Brands Will Not Cannibalise Sales Or Buyers, Says Wipro Consumer CEO
Wipro Consumer Care and Lighting Ltd., a subsidiary of Wipro Enterprises Pvt., has acquired three soap brands—Jo, Doy, and Bacter Shield—from Mumbai-based VVF India, marking its third acquisition over the past 12 months.
The acquisition is part of the consumer goods maker's strategy to tap the lower end of the country's Rs 28,000-crore soap market and enter new geographies in a bid to grab the number one crown from Hindustan Unilever Ltd.
Jo toilet soap has a significant role in the country's north, east, and west markets, while Doy operates in the premium soap segment. Bacter Shield has an antibacterial range of soap and handwash. These brands have a combined market share of 11%. Together, they recorded revenue of over Rs 210 crore during the financial year 2023, the company said in a release.
The company didn't disclose the deal value.
"The three new brands complement our existing portfolio and will give us a stronger foothold in key markets," Neeraj Khatri, chief executive officer of Wipro Consumer Care and Lighting, India and SAARC, told BQ Prime.
Wipro already sells brands such as Santoor, Yardley and Chandrika in the country. Santoor is the second-largest soap brand after HUL's Lifebuoy. In FY23, the brand reported sales of over Rs 2,650 crore.
Still, the new brands will not lead to cannibalisation of existing customers or sales, Khatri said.
A sub-popular segment, or products priced below Rs 25, comprises a big chunk of the toilet soap market. But this market has remained untapped by Wipro so far, said Khatri. Jo, he said, "perfectly" fits into the segment as it will help the company attract buyers put off by the price of Santoor.
Jo, for instance, will be priced below Rs 25 for a 100 gm pack as compared with Santoor's 100 gm pack worth Rs 35.
"Santoor caters to the popular price segment and does significantly well in the south and west, while Chandrika is a sub-premium brand and does well in certain markets, while Yardley is a premium play in soaps," he said.
Both Jo and Doy are expected to help Wipro Consumer penetrate deeper into the northern and eastern parts of the country, where Santoor isn't that big.
"North and east comprise 65% of sales for sub-popular brands," he said.
Wipro Consumer Care recorded sales of Rs 10,000 crore in FY23, half of which was generated from its overseas operations. In India, the company grew 17.7% to become the fastest-growing FMCG brand.
This year, however, Khatri expects growth to taper off in line with that of the industry due to an inflation-led consumption slowdown. "Our growth would probably be in high single digits this year, unlike last year, yet we are hoping to grow ahead of the industry," Khatri said. He expects the urban markets to drive sales, while rural demand may take time to recover.
Inorganic expansion has been Wipro's key growth strategy.
The latest deal marks the company's 15th acquisition so far. The other acquisitions by the company over the years include Glucovita, Chandrika, North-West, Unza, Yardley, Bio Essence, and Splash Corp.
In the past 12 months, the company has acquired two Kerala-based brands—Nirapara and Brahmins—as it seeks to consolidate its position in the market and expand beyond its traditional home and personal care offerings.
-
'Never Seen This Level Of Negativity': Sandeep Tandon Says The Next Rally May Be Closer Than You Think
Veteran investor Sandeep Tandon says foreign selling is easing, large-caps are due a comeback and mid-caps are crowded, while he turns positive on gold, power and pharma this Diwali.
-
Indians Stay With Family, Not In Hotels | The Reason Why
India still lacks enough clean, reliable and affordable hotels for budget-conscious travellers.
-
The Economic Imperative: Analysing The Material Driving Force Behind India-Canada Strategic Reset
This economic complementarity is further reinforced by deep institutional investment ties and talent mobility, which form the bedrock of the bilateral framework.
-
Medicine Pricing: Where Must Profit Stop?
India must confront excessive margins, hidden incentives and regulatory gaps that threaten the integrity of medicine.
-
Why Amazon And Flipkart Are Struggling To Beat Meesho In India's Smaller Cities
With 274 million users and lowest-cost logistics, Meesho is defending its value commerce crown against giants like Amazon and Flipkart.
-
High US Salaries, No Green Card Certainty: The Financial Calculation Facing Indian H-1B Families
The suspension of PERM processing at eight technology employers does not cancel existing H-1B visas. What it does is force a question many Indian families have been avoiding: is the US salary worth tying your career and family plans to one employer?
-
Swiggy vs Eternal: Food Delivery's Two Rivals Are No Longer In The Same Race
Eternal is building a private AI assistant, dark.ai. Swiggy is still working out how to make Instamart pay, with an operating loss of Rs 895 crore in the July-September quarter while Blinkit stayed profitable.
-
Where You Live Shapes How You Get To Work | The Reason Why
Two-wheelers are the most popular way to get to work in India, accounting for nearly 43% of workplace commutes.
-
Unhedged Position: Can India See An Indonesia-Style Time Correction?
The Nifty is trading below levels it first clocked in 2024. Is there, then, as I have suggested in the headline, potential that the current time correction drags on painfully for the next three-five, even ten years?
-
Navigating Friction And Energy Realities: An Analysis Of Marco Rubio's October Visit To India
Occurring at a critical juncture marked by stalled trade negotiations and escalating geopolitical pressures over global energy supplies, the visit offers a profound window into modern US-India relations.